Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2023-05-31 | OssDsign | Årsstämma har hållits i OssDsign AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-31 | OssDsign | Annual General Meeting held in OssDsign AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-24 | Penser Access | Penser Access: Exponentiell tillväxt för Catalyst - OssDsign | Pressreleaser | Visa Stäng |
|
||||
2023-05-24 | Redeye | Redeye: OssDsign Q1 - Steep acceleration of sales | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-23 | OssDsign | OssDsign AB (publ) publishes Q1 2023 Interim Report | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-23 | OssDsign | OssDsign AB (publ) publicerar delårsrapport för första kvartalet 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-09 | OssDsign | OssDsign AB: 1 000 patienter behandlade med OssDsign® Catalyst i USA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-09 | OssDsign | OssDsign AB: 1,000 patients treated with OssDsign® Catalyst in the U.S. | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
OssDsign AB: 1,000 patients treated with OssDsign® Catalyst in the U.S.OssDsign Catalyst has been very well received in the U.S. market since its launch in August 2021. In January OssDsign reported that 500 patients had been treated since launch, and at the beginning of May the number increased to 1,000 patients. ”OssDsign Catalyst is growing exponentially driven by a continuously growing customer base as well as broader usage within the hospitals and, in the last four months alone, we have doubled the number of patients treated. This is an outstanding development that highlights the potential for OssDsign Catalyst to become the preferred product for spinal fusion surgeries,” said Morten Henneveld, CEO of OssDsign. OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue. The product was launched in the U.S. in August 2021. The market clearance in the U.S. is based on preclinical results that surpass what is typically seen with other synthetic bone grafts in the most demanding preclinical model for spinal fusion – the Boden model. OssDsign continues to accelerate a robust program of gathering clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry, and the clinical study TOP FUSION, in which patient enrolment was completed in April 2022. For further information, please contact: Certified Adviser: |
||||
2023-04-27 | OssDsign | OssDsign AB: OssDsign publishes Annual Report 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-27 | OssDsign | OssDsign AB: OssDsign publicerar Årsredovisning 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-27 | OssDsign | OssDsign AB: KALLELSE TILL ÅRSSTÄMMA I OSSDSIGN AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-27 | OssDsign | OssDsign AB: NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN OSSDSIGN AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-27 | OssDsign | OssDsign AB: OssDsign når kommersiell milstolpe med 750 implantat sålda i Tyskland | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-04-27 | OssDsign | OssDsign AB: OssDsign reaches commercial milestone of 750 implants sold in Germany | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-20 | OssDsign | OssDsign AB: OssDsign increases operational efficiency and reduces Cranial PSI lead time by up to 40 percent | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-20 | OssDsign | OssDsign AB: OssDsign effektiviserar sin tillverkning och minskar ledtiden för Cranial PSI med upp till 40 procent | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-14 | OssDsign | OssDsign AB: OssDsign når kommersiell milstolpe - 200 sålda implantat i Frankrike | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-03-14 | OssDsign | OssDsign AB: OssDsign reaches commercial milestone of 200 implants in France | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-22 | Penser Access | Penser Access: Inne i kraftfull tillväxtfas - OssDsign | Pressreleaser | Visa Stäng |
|
||||
2023-02-22 | Redeye | Redeye: OssDsign Q4 - Delivering well in tough conditions | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-21 | OssDsign | OssDsign AB (publ) publishes Year-end Report 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-02-21 | OssDsign | OssDsign AB (publ) publicerar bokslutskommuniké 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-10 | OssDsign | OssDsign AB: OssDsign Catalyst 1cc är nu lanserad och fullt tillgänglig på den amerikanska marknaden | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-09 | OssDsign | OssDsign AB: OssDsign når milstolpe - 500 patienter behandlade med OssDsign® Catalyst i USA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-01-04 | OssDsign | OssDsign AB: Den första patientrapporten med OssDsign Catalyst visar fullständig ryggradsfusion sex månader efter steloperation | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-12-16 | OssDsign | OssDsign AB: Långtidsuppföljning fortsätter visa låga komplikationsnivåer vid behandling med OssDsign Cranial PSI | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-29 | OssDsign | OssDsign AB completes a directed new share issue raising proceeds of approximately SEK 65.6 million | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-29 | OssDsign | OssDsign AB genomför en riktad nyemission av aktier och tillförs därigenom cirka 65,6 miljoner kronor | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-29 | OssDsign | OssDsign AB avser att genomföra en riktad nyemission av aktier | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-29 | OssDsign | OssDsign AB intends to carry out a directed new share issue | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-29 | Penser Access | Penser Access: Interview with OssDsign - Erik Penser Bank - 28 november 2022 | Analyser | Visa Stäng |
|
||||
2022-11-23 | Penser Access | Penser Access: Ytterligare ett försäljningsmässigt starkt kvartal - OssDsign | Analyser | Visa Stäng |
|
||||
2022-11-23 | Redeye | Redeye: OssDsign Q3 - Catalyst positively surprises, but still a difficult climate | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-11-22 | OssDsign | OssDsign AB (publ) publicerar delårsrapport för tredje kvartalet 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-22 | OssDsign | OssDsign AB (publ) publishes Q3 2022 Interim Report | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-17 | OssDsign | OssDsign AB: De första resultaten från en långtidsuppföljning av OssDsign Catalyst visar noll procent produktrelaterade komplikationer | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-09 | OssDsign | OssDsign AB: OssDsign når milstolpen 100 patienter i sitt PROPEL-register tidigare än väntat | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-11-03 | OssDsign | OssDsign AB: OssDsign utökar Catalyst-portföljen och lanserar en ny produkt anpassad för fler typer av kirurgiska ingrepp | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-29 | OssDsign | OssDsign AB: BioStock Investor Meeting: Interview with OssDsign | Pressreleaser | Visa Stäng |
|
||||
2022-09-29 | OssDsign | OssDsign AB: BioStock Investor Meeting: Intervju med OssDsign | Pressreleaser | Visa Stäng |
|
||||
2022-09-26 | OssDsign | OssDsign AB: Ny vetenskaplig publikation av den hittills största fallstudien av OssDsign Cranial PSI i USA visar positiva behandlingsresultat samt total avsaknad av implantatrelaterade komplikationer | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-09-22 | OssDsign | OssDsign AB: BioStock Investor Meeting: OssDsign presents | Pressreleaser | Visa Stäng |
|
||||
2022-09-22 | OssDsign | OssDsign AB: BioStock Investor Meeting: OssDsign presenterar | Pressreleaser | Visa Stäng |
|
||||
2022-09-13 | Penser Access | Penser Access: Interview with OssDsign - Erik Penser Bank - September 12th 2022 | Analyser | Visa Stäng |
|
||||
2022-08-24 | Penser Access | Penser Access: USA-marknaden driver kraftig försäljningsökning - OssDsign | Analyser | Visa Stäng |
|
||||
2022-08-24 | Redeye | Redeye: OssDsign - A taste of a better market outlook | Analyser | Ladda ner | Visa Stäng |
|
||||
2022-08-23 | OssDsign | OssDsign AB (publ) publicerar delårsrapport för andra kvartalet 2022 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2022-08-23 | OssDsign | OssDsign AB (publ) publishes Q2 2022 Interim Report | Pressreleaser | Ladda ner | Visa Stäng |
|